Tests long-term safety of inhaled treprostinil in people with lung scarring
Tests inhaled treprostinil's long-term safety in adults with progressive pulmonary fibrosis.
Plain-language title generated from the registry record
Registry title: Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
Key facts
- Where
- Amiens, Bobigny, Bron, Caen, Marseille, Paris, Reims, Rennes, Rouen, Toulouse, and Tours, FranceSee the 12 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people who took part in an earlier inhaled treprostinil study (RIN-PF-301, RIN-PF-303 or RIN-PF-305) and want to keep taking it. It checks long-term safety.
- Age
- 40 years or older.
- Sex
- Men and women can join.
- Disease stage
- Idiopathic pulmonary fibrosis or progressive pulmonary fibrosis.
- Earlier treatment
- Must have taken part in Study RIN-PF-301, RIN-PF-303 or RIN-PF-305. Must have stayed on study drug and finished all visits, or been in the study when the Sponsor stopped it for reasons other than safety.
Main reasons for not taking part
- Pregnant or breastfeeding
- Taking part in another study that gives a medical intervention, such as a procedure, device or medicine
- The investigator thinks joining would be a risk to your overall health
Read by machine on 12 November 2026.
Where in France
- Chu Amiens PicardieAmiens, FranceNo longer taking part
- AP-HP Hôpital AvicenneBobigny, FranceNo longer taking part
- Hospices Civils De Lyon - Université Hospital of LyonBron, FranceNo longer taking part
- Chu Caen NormandieCaen, FranceNo longer taking part
- Hopital Nord AP-HM (Assistance Publique Hôpitaux De Marseille - Centre Hospitalier Régional de MarseilleMarseille, FranceNo longer taking part
- AP-HP Hopital Europeen Georges PompidouParis, FranceNo longer taking part
- Hôptial BichatParis, FranceNo longer taking part
- Centre Hospitalier Universitaire de Reims Hôpital Maison BlancheReims, FranceNo longer taking part
- Hôpital PontchaillouRennes, FranceNo longer taking part
- CHU Rouen Hopital Charles NicolleRouen, FranceNo longer taking part
- Hopital LarreyToulouse, FranceNo longer taking part
- Hopital BretonneauTours, FranceNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- United Therapeutics
- Trial code
- NCT04905693
- Record updated
- 19 October 2026
- Original description
Study RIN-PF-302 is designed to evaluate the long-term safety and tolerability of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis.Read full original descriptionShow less
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease (TETON-OLE)
Study RIN-PF-302 is designed to evaluate the long-term safety and tolerability of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis.
Inclusion: Subject gives voluntary informed consent to participate in the study; The subject participated in Study RIN-PF-301, Study RIN-PF-303, or Study RIN-PF-305 and remained on study drug and completed all scheduled study visits or was enrolled in Study RIN-PF-301, Study RIN-PF-303, or Study RIN-PF-305 at the time that the study or study subject was discontinued by the Sponsor for reasons other than safety; Women of childbearing potential must be non-pregnant (as confirmed by a urine pregnancy test at OLE Entry Visit) and non-lactating, and will agree to abstain from intercourse (when it is in line with their preferred and usual lifestyle) or use 2 medically acceptable, highly effective forms of contraception for the duration of the study, and at least 30 days after discontinuing study drug; Males with a partner of childbearing potential must agree to use a condom for the duration of treatment and for at least 48 hours after discontinuing study drug; In the opinion of the Investigator, the subject is able to communicate effectively with study personnel, and is considered reliable, willing, and likely to be cooperative with protocol requirements, including attending all study visits.
Exclusion: Use of any other investigational drug/device or participation in any investigational study in which the subject received a medical intervention (ie, procedure, device, medication/supplement). Subjects participating in non-interventional, observational, or registry studies are eligible; Subject is pregnant or lactating; In the opinion of the Investigator, enrollment in Study RIN-PF-302 would represent a risk to the subject's overall health.